Out-licensing: Genito-urinary/Gender Related Medicine Male/Prostatitis

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Up-to-date access to technology licensing opportunities worldwide.

Displaying 1..2 of 2 - per page
Order by

Antroquinonol® is a non-toxic, highly effective cancer treatment agent, developed using natural organic chemistry. More

This technology builds on the surprising discovery that pentosan polysulfate can cause regression of scarring and lesions in prostatic tissue. More

Displaying 1..2 of 2 - per page
Order by

Therapeutic target: Genito-urinary del; Gender related medicine male del; Prostatitis del

Industry sector: Animal health; Biotechnology; Diagnostic; Drug delivery; Drug discovery; Medical device; Pharmaceutical; Research tools
Development phase: Early Stage; Preclinical; Phase I; Phase I/II; Phase II; Phase III; Phase III/IV; Preregistration; Registered

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.